OBJECTIVES: Patient adherence with hypertension therapy is a leading cause for uncontrolled blood pressure in the United States. The Anti-hypertensive Adherence Survey (aHA Survey) was developed as a patient self-reported assessment of therapy adherence. This study reports the psychometric properties and construct validity of the tool. METHODS: The aHA Survey was administered to hypertensive patients in a cross-sectional, non-interventional multisite study. The aHA Survey comprises 25 items organized within six domains: Knowledge (9 items), Medical Acceptance (3 items), Compliance (6 items), Finance (1 item), Willingness to Change (4 items) and Depression (2 items). The aHA scoring algorithm assigns points and designates intervention prompts based on patient's responses to individual items across each domain. Construct validity of the aHA Survey was evaluated using an extension of the 1-parameter Rasch model for polytomous response data when the items within a domain have unique rating domains and recall periods, the Partial Credit Model. Unidimensionality was evaluated for the full instrument and related scoring using goodness-of-fit statistics with an expected range between 0.60-1.40. Reliability of the scores was assessed using the Rasch person reliability estimate and the internal structure evaluated using Principal Components Analysis. RESULTS: A total of 273 patients ere included in the study (50.9% male, 89.7% Caucasian). Item fit was acceptable for all items on the aHA Survey. The overall reliability for aHA Survey was moderate to high (alpha ϭ 0.84) and 33.3% of the underlying variance in adherence was measured by the items on the instrument. CONCLUSIONS: This study demonstrates the utility of measuring a multi-dimensional phenomenon such as adherence in patient's hypertensive therapy using a brief 25-item assessment. The current items and related scoring algorithm indicate good construct validity and reliability; which is imperative for clinical utility. Validation against real-world data will be considered in the next phase of research.
OBJECTIVES: Gout is one of the most common inflammatory arthritides; it is commonly managed in primary care in the UK and has been associated with poor cardiovascular (CV) outcomes. Allopurinol use has been associated with improved outcomes, particularly at a higher dose (Ͼ600mg/day); however, published studies have shown that prescribed doses in the UK are 300mg or less. Adherence to allopurinol has not been well evaluated in the UK; we estimate the impact of adherence to allopurinol on CV in gout patients in the UK. METHODS: The Health Improvement Network (THIN) database from 1990 to 2009 was examined; patients aged 18ϩ were identified using Read and drug codes. The CV-related outcomes were myocardial infarction (MI), heart failure, stroke, peripheral thrombosis, angina and coronary artery bypass. Adherence was measured using proportion of days covered (PDC). Descriptive statistics were calculated and Kaplan-Meir survival curves were constructed for different levels of adherence (PDC in quartiles). Analyses were performed in a subset of patients that experienced a particular CV event during the observation period. RESULTS: A total of 91,665 gout patients were identified, 39,747 of which were prescribed allopurinol; of these, 9% had MI, 18% had heart failure, 15% had stroke, 4% had thrombosis, 16% had angina and 5% had coronary artery bypass. Mean PDC in patients prescribed with allopurinol was 0.72 (SDϮ0.28). Higher PDC was associated with increased survival time in all CV events except for angina. PDC Ͼ 0.75 resulted in substantially greater survival time. High adherence has the greatest impact in MI and coronary artery bypass. CONCLUSIONS: Greater adherence to allopurinol appears to be associated with better CV outcome in all conditions except angina. A more profound effect in PDC higher than 0.75 suggests that high adherence is needed to achieve clinical benefit. [SD 165.6 ] days in fixed-dose combinations with HCT. CONCLUSIONS: Overall, findings based on real-life prescription data suggest better patient persistence with unfixed and fixed-dose OLM combinations compared to respective VAL combinations. In terms of persistance not all angiotensin receptor blockers perform equal rather hint at patient-individual treatment. Further research is needed to confirm these first results.
PCV104 PERSISTENCE IN HYPERTENSION TREATMENT WITH OLMESARTAN MEDOXOMIL VERSUS VALSARTAN -ANALYSIS OF REAL-LIFE PRESCRIPTION DATA IN GERMANY

PCV105 USING THEORY OF REASONED ACTION VARIABLES TO PREDICT AND IMPROVE STATIN ADHERENCE
Schwartz JS, Bleakley A, Kydd S, Fishbein M University of Pennsylvania, Philadelphia, PA, USA OBJECTIVES: Patient adherence with prevention and treatment of chronic disease is challenging. Communication theory has potential to improve effectiveness of interventions to improve adherence. This study used Theory of Reasoned Action (TRA) variables to examine behavioral, normative injunctive and control beliefs associated with statin adherence; association of beliefs with intentions and adherence; and variation among subgroups (sex, race, treatment duration, primary vs. secondary prevention). METHODS: Cardiology and primary care academic health system patients prescribed statins January 2007 to December 2009 (nϭ101,492). Elicitation Study: Semi-structured telephone interviews (nϭ40). Mail Survey: Random sample stratified by race and prior CVD events (Nϭ1829). Causal path regression coefficients were compared using multi-group structural equation modeling, stratified by race, gender and age. RESULTS: Elicitation Study: Respondents perceived statin therapy as beneficial and reported supportive social norms and good self-efficacy. Adherence failure was associated primarily with inability to act on intentions rather than lack of intention. Mail Survey: Responseϭ50.2%; (53% male, 61% CVD event; 39% AA; mean age 65). AAs & women had lower intentions; AA lower self-efficacy and normative pressure; older respondents higher self-efficacy; secondary prevention higher normative pressure and behavioral beliefs. Males were higher and those with perceived side effects lower for all three reasoned action intention predictors. Non-event group: R2 intentionsϭ0.41. Adherence was associated most strongly with attitudes. AAs were lower on all reasoned action intention predictors. CVD event group: R2 Intentionsϭ0.20. Adherence was most strongly associated with attitudes and self-efficacy. No socio-demographic variable differentiated among intention predictors. CONCLUSIONS: Intentions and adherence were associated most strongly with behavioral, normative and self-efficacy beliefs and differed across demographic and prior event subgroups, suggesting potential to improve adherence using targeted messages based on reasoned action variables addressing subgroup specific beliefs. Intentions and adherence were predicted better for primary than secondary prevention, suggesting greater potential for TRA-based targeted messages for those without a previous CVD event. 
OBJECTIVES:
In this study, we seek to measure the association between physicianrated adherence to antihypertensive treatment and blood pressure outcomes. Prior to the study, we hypothesized that systolic and diastolic blood pressure outcomes were also related with patient and physician variables. Therefore, we also seek to determine the impact of these variables on the outcome. METHODS: Unlike prior adherence studies, which have consulted small sample sizes by means of timeconsuming and complex questionnaires, our research pools the findings from six Valsartan studies, thereby evaluating 15,583 patients, while utilizing a simple and cost-effective survey method. Adherence was measured using a four-item yes/no Basel Assessment for Adherence Scale (BAAS), in which a "yes" answer on any item classified a patient as non-adherent. The measurements were performed at baseline and at 90 days. Hierarchical logistic regression was used to identify patientand physician-related determinants. RESULTS: Our results indicate that inadequate blood pressure control correlates with poor adherence at baseline and 90 days. The mean absolute difference in blood pressure between those who were adherent (70% of the patient population) and those who were not was 5 to 19 mmHg (pϽ0.001). Every adherent patient was likely to decrease his systolic and diastolic blood pressure by 2.3 and 1.3 mmHg, respectively (pϽ0.001). The majority of the variability in blood pressure values, however, was due to patient variables, many of which can be managed with medical care, or identified in patients with higher risks, poor adherence, or poly-pharmacy. CONCLUSIONS: Physician-reported adherence by means of a short patient BAAS questionnaire is a direct, simple and especially inexpensive method to assess adherence status. This method can be easily integrated into routine clinical practice and provides evidence that adherence is positively correlated with blood pressure reduction in hypertensive patients. However, patient-related variables also correlate strongly with the outcome and demand further investigation.
PCV108 DERIVING UTILITY VALUES FROM THE GENERAL POPULATION FOR DRONEDARONE IN THE TREATMENT OF ATRIAL FIBRILLATION
Adams J 1 , Lee J 2 , Gonzalo F 3 1 Pretium, Sydney, NSW, Australia, 2 Sanofi Australia Pty Ltd, Macquarie Park, NSW, Australia, 3 Sanofi-Aventis Australia Pty Limited, Macquarie Park, Australia OBJECTIVES: To derive Australian utility values for different health states associated with a new antiarrhythmic drug, dronedarone, for the treatment of patients with atrial fibrillation (AF). METHODS: OEOne hundred nineteen participants were recruited by an independent research company. They ranged from 18 -69 years (mean age 44 years). Participants were presented information about AF, as well as treatment for their disease. Participants were then presented with 8 health states describing AF and its treatment and were asked to value these using a standard gamble technique. RESULTS: The results demonstrated that participants had a strong understanding of the condition and its treatment, and successfully valued the health states, applying values derived for the 8 health states (AF, mild stroke, moderate stroke, severe stroke, myocardial infarction, mild stroke and myocardial infarction, moderate stroke and myocardial infarction, and severe stroke and myocardial infarction) and their varying severity levels in a logical sequence. Values ranged from 0.41 (SD ϭ 0.25) for the health state describing a patient with severe stroke and myocardial infarction, to 0.78 (SD ϭ 0.22) describing a patient experiencing a mild stroke. CONCLUSIONS: Overall, the results of this study show that a sample of the general Australian population is able to use the standard gamble successfully to derive utility values for atrial fibrillation health states. 
PCV109 MEASURING HEALTH UTILITY IN THAI STROKE PATIENTS
OBJECTIVES:
To measure health utility of stroke patients and to compare those using 4 measurement methods, i.e., visual analogue scale (VAS), standard gamble (SG), time trade off (TTO) and European Quality of Life-5 Dimensions (EQ-5D). METHODS: All 284 stroke patients at Ratchaburi Hospital were recruited between August to October 2009 with the following criteria; aged over 20 years, contained the Barthel ADL Index scores of over 25 and be able to communicate. The patients were invited to participate in the study and respond to the questionnaire. Six parts of the questionnaire included general information, the Barthel ADL index, VAS, SG, TTO and Thai EQ-5D. Difficulty of each assessment method was ranked. Data were then analyzed by ANOVA. RESULTS: The mean health utility of stroke patients measured by VAS, SG, and EQ-5D were 0.70, 0.72, and 0.55, respectively. However, the score evaluated by TTO could not be measured since the questionnaires were too difficult for patients to understand. In addition, there was no significant difference between health utility measured by VAS and SG. However, a significant difference between VAS and EQ-5D, and between SG and EQ-5D were found. CONCLUSIONS: Thai stroke patients' health utility was moderate level. However, there was a significant difference in utilities obtained from different methods. Boehringer Ingelheim, Ingelheim, Germany, 3 HHS -General Hospital, Hamilton, ON, Canada BACKGROUND: Venous thrombembolism (VTE) is a frequent event in the developed world and is associated with serious long-term complications, including postthrombotic syndrome, recurrent VTE, poor health-related quality of life (HRQL) and death. VTE can manifest as deep venous leg thrombosis or lung embolism. OBJECTIVES: To examine factors associated with HRQL in a randomized, doubleblind phase III trial comparing dabigatran etexilate to dose-adjusted warfarin in acute VTE (RE-COVER). METHODS: Following parenteral treatment of acute VTE, patients were randomized to oral dabigatran etexilate or warfarin for six months. Patients completed the EQ-5D questionnaire at baseline, three and six months. EQ-5D index scores (UK weights) were regressed on treatment, time since index VTE, age, gender, race, ethnicity, smoking status, body weight, and various clinical characteristics/conditions. Multivariate Censored Least Absolute Deviations (CLAD), Tobit and Ordinary Least Squares (OLS) regression methods were compared. EQ-5D questionnaire responses were also examined to identify the most affected domains. RESULTS: There were 1245 patients on warfarin and 1264 on dabigatran with valid EQ-5D scores at baseline; 1149 and 1150, respectively, at trial end. After controlling for covariates, the following factors were statistically significant (pϽ0.05; CLAD) and exhibited the largest magnitude changes in EQ-5D index scores (from largest to smallest): 6 months post VTE (ϩ0.21), 3 months post VTE (ϩ0.192), recurrent DVT (-0.17), underweight (-0.09), female (-0.08), morbidly obese (-0.07), recurrent pulmonary embolism (-0.06), heart failure (-0.05), age Ͼ65 (-0.04) and clinically relevant bleeding (-0.03). There were no statistically significant differences between treatment groups. All regression methods yielded comparable results. Domains most affected by VTE were mobility, usual activities and pain/discomfort. CONCLUSIONS: Results of the RE-COVER trial demonstrate that HRQL after VTE is largely dependent on the time from event rather than choice of treatment. Further, significant differences in HRQL were associated with certain clinical and patient characteristics.
PCV110
HEALTH-RELATED QUALITY OF LIFE AFTER VENOUS THROMBOEMBOLISM
PCV111 ECONOMIC BURDEN AND HEALTH-RELATED QUALITY OF LIFE IN EUROPEAN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE
Marrett E 1 , Dibonaventura MD 2 , Zhang Q 3 1 Merck, Sharp & Dohme, Whitehouse Station, NJ, USA, 2 Kantar Health, New York, NY, USA, 3 Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA OBJECTIVES: Assess the burden of peripheral arterial disease (PAD) on patient health-related quality of life (HRQoL), work productivity, health care resource use, and to estimate the related direct and indirect costs in patients with PAD in five EU countries. METHODS: Cross-sectional data were obtained from the 2010 EU National Health and Wellness Survey, an internet-based survey in adults. Patients with PAD were identified based on a self-reported PAD diagnosis. We assessed HRQoL (SF-12v2 and estimated health utility), healthcare resource use in previous 6 months and work productivity in previous 7 days (Work Productivity and Activity Impairment questionnaire) reported by respondents with and without self-reported PAD diagnosis. Resource use and work productivity loss were monetized on an annual basis to provide per-person cost estimates (2010 Euros). RESULTS: We identified 743 respondents with (France 278, Germany 151, UK 69, Italy 159, Spain 86) and 57,062 without PAD. Compared to non-PAD respondents, those self-reporting PAD were older (mean age 58.1 vs. 46.3 years), had more comorbidities, reported lower mean (SD) HRQoL scores [mental summary: 43.4 (11.4) versus 46.6 (10.6); physical summary: 37.6 (11.2) versus 48.8 (9.7); health utilities: 0.63 (0.12) versus 0.73 (0.13)], greater mean (SD) percentage of absenteeism [12.1 (27.7) versus 5.4 (19.2)], higher mean (SD) health care utilization over 6 months [physician office visits 11.9 (13.7) versus 5.3 (7.4), emergency room visits 0.40 (1.6) versus 0.19 (1.1), hospitalizations 0.39 (1.5) versus 0.13 (1.2)], and higher total median (SD) direct [1,329 (3,198) versus 544 (2,630) €] and indirect [8,850 (10,244) versus 4,015 (7,135) €] yearly costs. CONCLUSIONS: Respondents with self-reported PAD reported lower HRQoL scores and generated greater direct and indirect costs suggesting that PAD poses a significant health burden to patients and society in Europe. Better management of PAD may improve patient quality of life and reduce societal costs associated with the disease.
PCV112 A COMPARISON OF EUROPEAN HEALTH CARE SYSTEMS ON STROKE PREVENTION IN ATRIAL FIBRILLATION -INTERIM RESULTS OF A PATIENT SATISFACTION SURVEY
Oberdiek A 1 , Sandberg A 1 , Franczok E 2 1 Daiichi Sankyo Europe GmbH, Munich, Germany, 2 Harris Interactive AG, Munich, Germany OBJECTIVES: To evaluate and compare patient satisfaction in stroke prevention in atrial fibrillation (SPAF) in Europe. Interim results are presented to initiate discussions and guide analysis for the main survey. METHODS: A survey based on the Commonwealth Fund Survey (2008) for chronically ill adults is applied to patients with SPAF, with few disease-specific adjustments made. The survey is carried out with structured randomized anonymous telephone interviews in France, Germany, Italy, Spain and UK, screening for respondents with AF aged over 18. Total pilot sample size is 152 respondents, evenly divided per country. RESULTS: The pilot results indicate differences to other chronically ill patients and country variations. Mean age of respondents is 67, 50% female. Overall, 43% of the respondents are totally satisfied with their health care system (highest in the UK: 57%). Most frequent co-morbidities are hypertension (66%) and heart disease, including heart attack (53%) beside arthritis, depression, chronic lung problems, diabetes, cancerwith an average of 2,2 co-morbidities per respondent, regularly on 5,4 different prescriptions. Ten percent had a period when they were uninsured (highest with 20% in the UK) and 11% had problems with unpaid medication (highest in Germany with 33%) or refusal of payment by the insurance 9% (highest in France with 27%).
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